Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1999 Feb;79(5-6):807–813. doi: 10.1038/sj.bjc.6690129

GR-891: a novel 5-fluorouracil acyclonucleoside prodrug for differentiation therapy in rhabdomyosarcoma cells

J A Marchal 1, J Prados 2, C Melguizo 2, J A Gómez 2, J Campos 3, M A Gallo 3, A Espinosa 3, N Arena 4, A Aránega 1
PMCID: PMC2362655  PMID: 10070873

Abstract

Differentiation therapy provides an alternative treatment of cancer that overcomes the undesirable effects of classical chemotherapy, i.e. cytotoxicity and resistance to drugs. This new approach to cancer therapy focuses on the development of specific agents designed to selectively engage the process of terminal differentiation, leading to the elimination of tumorigenic cells and recovery of normal cell homeostasis. A series of new anti-cancer pyrimidine acyclonucleoside-like compounds were designed and synthesized by structural modifications of 5-fluorouracil, a drug which causes considerable cell toxicity and morbidity, and we evaluated their applicability for differentiation therapy in human rhabdomyosarcoma cells. We tested the pyrimidine derivative GR-891, (RS)-1-{[3-(2-hydroxyethoxy)-1-isopropoxy]propyl}-5-fluorouracil, an active drug which shows low toxicity in vivo and releases acrolein which is an aldehyde with anti-tumour activity. Both GR-891 and 5-fluorouracil caused time- and dose-dependent growth inhibition in vitro; however, GR-891 showed no cytotoxicity at low doses (22.5 μmol l−1 and 45 μmol l−1) and induced terminal myogenic differentiation in RD cells (a rhabdomyosarcoma cell line) treated for 6 days. Changes in morphological features and in protein organization indicated re-entry in the pathway of muscular maturation. Moreover, GR-891 increased adhesion capability mediated by the expression of fibronectin, and did not induce overexpression of P-glycoprotein, the mdr1 gene product, implicated in multidrug resistance. New acyclonucleoside-like compounds such as GR-891 have important potential advantages over 5-fluorouracil because of their lower toxicity and their ability to induce myogenic differentiation in rhabdomyosarcoma cells. Our results suggest that this drug may be useful for differentiation therapy in this type of tumour. 1999 Cancer Research Campaign

Keywords: acyclonucleoside prodrugs, 5-fluorouracil, differentiation therapy, multidrug resistance, rhabdomyosarcoma

Full Text

The Full Text of this article is available as a PDF (613.5 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aguanno S., Bouchè M., Adamo S., Molinaro M. 12-O-tetradecanoylphorbol-13-acetate-induced differentiation of a human rhabdomyosarcoma cell line. Cancer Res. 1990 Jun 1;50(11):3377–3382. [PubMed] [Google Scholar]
  2. Beere H. M., Hickman J. A. Differentiation: a suitable strategy for cancer chemotherapy? Anticancer Drug Des. 1993 Aug;8(4):299–322. [PubMed] [Google Scholar]
  3. Borden E. C., Lotan R., Levens D., Young C. W., Waxman S. Differentiation therapy of cancer: laboratory and clinical investigations. Cancer Res. 1993 Sep 1;53(17):4109–4115. [PubMed] [Google Scholar]
  4. Burridge K., Feramisco J. R. Non-muscle alpha actinins are calcium-sensitive actin-binding proteins. Nature. 1981 Dec 10;294(5841):565–567. doi: 10.1038/294565a0. [DOI] [PubMed] [Google Scholar]
  5. Capetanaki Y. G., Ngai J., Lazarides E. Characterization and regulation in the expression of a gene coding for the intermediate filament protein desmin. Proc Natl Acad Sci U S A. 1984 Nov;81(22):6909–6913. doi: 10.1073/pnas.81.22.6909. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Carter R. L., McCarthy K. P., Machin L. G., Jameson C. F., Philp E. R., Pinkerton C. R. Expression of desmin and myoglobin in rhabdomyosarcomas and in developing skeletal muscle. Histopathology. 1989 Dec;15(6):585–595. doi: 10.1111/j.1365-2559.1989.tb01624.x. [DOI] [PubMed] [Google Scholar]
  7. Chen Z. X., Breitman T. R. Tributyrin: a prodrug of butyric acid for potential clinical application in differentiation therapy. Cancer Res. 1994 Jul 1;54(13):3494–3499. [PubMed] [Google Scholar]
  8. Crouch G. D., Helman L. J. All-trans-retinoic acid inhibits the growth of human rhabdomyosarcoma cell lines. Cancer Res. 1991 Sep 15;51(18):4882–4887. [PubMed] [Google Scholar]
  9. Crouch G. D., Kalebic T., Tsokos M., Helman L. J. Ara-C treatment leads to differentiation and reverses the transformed phenotype in a human rhabdomyosarcoma cell line. Exp Cell Res. 1993 Feb;204(2):210–216. doi: 10.1006/excr.1993.1026. [DOI] [PubMed] [Google Scholar]
  10. De Giovanni C., Lollini P. L., Dolcetti R., Landuzzi L., Nicoletti G., D'Andrea E., Scotland K., Nanni P. Uncoupling of growth inhibition and differentiation in dexamethasone-treated human rhabdomyosarcoma cells. Br J Cancer. 1993 Apr;67(4):674–679. doi: 10.1038/bjc.1993.125. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Degos L. Un concept nouveau: le traitement par différenciation de la cellule maligne de l'homme. Bull Acad Natl Med. 1995 Nov;179(8):1689–1700. [PubMed] [Google Scholar]
  12. Enomoto M. I., Boettiger D., Menko A. S. Alpha 5 integrin is a critical component of adhesion plaques in myogenesis. Dev Biol. 1993 Jan;155(1):180–197. doi: 10.1006/dbio.1993.1017. [DOI] [PubMed] [Google Scholar]
  13. Eyden B. P. Brief review of the fibronexus and its significance for myofibroblastic differentiation and tumor diagnosis. Ultrastruct Pathol. 1993 Nov-Dec;17(6):611–622. doi: 10.3109/01913129309027797. [DOI] [PubMed] [Google Scholar]
  14. Farquhar D., Chen R., Khan S. 5'-[4-(Pivaloyloxy)-1,3,2-dioxaphosphorinan-2-yl]-2'-deoxy-5-fluorouridine: a membrane-permeating prodrug of 5-fluoro-2'-deoxyuridylic acid (FdUMP). J Med Chem. 1995 Feb 3;38(3):488–495. doi: 10.1021/jm00003a012. [DOI] [PubMed] [Google Scholar]
  15. Fuqua S. A., Fitzgerald S. D., McGuire W. L. A simple polymerase chain reaction method for detection and cloning of low-abundance transcripts. Biotechniques. 1990 Aug;9(2):206–211. [PubMed] [Google Scholar]
  16. Gabbert H. E., Gerharz C. D., Biesalski H. K., Engers R., Luley C. Terminal differentiation and growth inhibition of a rat rhabdomyosarcoma cell line (BA-HAN-1C) in vitro after exposure to retinoic acid. Cancer Res. 1988 Sep 15;48(18):5264–5269. [PubMed] [Google Scholar]
  17. Germann U. A. P-glycoprotein--a mediator of multidrug resistance in tumour cells. Eur J Cancer. 1996 Jun;32A(6):927–944. doi: 10.1016/0959-8049(96)00057-3. [DOI] [PubMed] [Google Scholar]
  18. Gundersen G. G., Khawaja S., Bulinski J. C. Generation of a stable, posttranslationally modified microtubule array is an early event in myogenic differentiation. J Cell Biol. 1989 Nov;109(5):2275–2288. doi: 10.1083/jcb.109.5.2275. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Hazelton B. J., Houghton J. A., Parham D. M., Douglass E. C., Torrance P. M., Holt H., Houghton P. J. Characterization of cell lines derived from xenografts of childhood rhabdomyosarcoma. Cancer Res. 1987 Aug 15;47(16):4501–4507. [PubMed] [Google Scholar]
  20. Herrera-Gayol A., Royal A., Babaï F. Correlation between cell differentiation stage, types of invasion, and hematogenous metastasis in experimental rhabdomyosarcomas. Exp Mol Pathol. 1995 Aug;63(1):1–15. doi: 10.1006/exmp.1995.1025. [DOI] [PubMed] [Google Scholar]
  21. Langbein L., Kosmehl H., Katenkamp D., Neupert G., Stiller K. J. Experimentally induced murine rhabdomyosarcomas--correlation between cellular contacts, matrix formation and cellular differentiation. Differentiation. 1990 Sep;44(3):185–196. doi: 10.1111/j.1432-0436.1990.tb00617.x. [DOI] [PubMed] [Google Scholar]
  22. Le Moigne A., Martelly I., Barlovatz-Meimon G., Franquinet R., Aamiri A., Frisdal E., Bassaglia Y., Moraczewski G., Gautron J. Characterization of myogenesis from adult satellite cells cultured in vitro. Int J Dev Biol. 1990 Mar;34(1):171–180. [PubMed] [Google Scholar]
  23. Lesuffleur T., Kornowski A., Augeron C., Dussaulx E., Barbat A., Laboisse C., Zweibaum A. Increased growth adaptability to 5-fluorouracil and methotrexate of HT-29 sub-populations selected for their commitment to differentiation. Int J Cancer. 1991 Nov 11;49(5):731–737. doi: 10.1002/ijc.2910490517. [DOI] [PubMed] [Google Scholar]
  24. Lesuffleur T., Kornowski A., Luccioni C., Muleris M., Barbat A., Beaumatin J., Dussaulx E., Dutrillaux B., Zweibaum A. Adaptation to 5-fluorouracil of the heterogeneous human colon tumor cell line HT-29 results in the selection of cells committed to differentiation. Int J Cancer. 1991 Nov 11;49(5):721–730. doi: 10.1002/ijc.2910490516. [DOI] [PubMed] [Google Scholar]
  25. Lollini P. L., De Giovanni C., Del Re B., Landuzzi L., Nicoletti G., Prodi G., Scotlandi K., Nanni P. Myogenic differentiation of human rhabdomyosarcoma cells induced in vitro by antineoplastic drugs. Cancer Res. 1989 Jul 1;49(13):3631–3636. [PubMed] [Google Scholar]
  26. Marchal J. A., Prados J., Melguizo C., Fernández J. E., Vélez C., Alvarez L., Aránega A. Actinomycin D treatment leads to differentiation and inhibits proliferation in rhabdomyosarcoma cells. J Lab Clin Med. 1997 Jul;130(1):42–50. doi: 10.1016/s0022-2143(97)90057-3. [DOI] [PubMed] [Google Scholar]
  27. McAllister R. M., Melnyk J., Finkelstein J. Z., Adams E. C., Jr, Gardner M. B. Cultivation in vitro of cells derived from a human rhabdomyosarcoma. Cancer. 1969 Sep;24(3):520–526. doi: 10.1002/1097-0142(196909)24:3<520::aid-cncr2820240313>3.0.co;2-m. [DOI] [PubMed] [Google Scholar]
  28. Melguizo C., Prados J., Aneiros J., Fernandez J. E., Velez C., Aranega A. Differentiation of a human rhabdomyosarcoma cell line after antineoplastic drug treatment. J Pathol. 1995 Jan;175(1):23–29. doi: 10.1002/path.1711750105. [DOI] [PubMed] [Google Scholar]
  29. Melguizo C., Prados J., Marchal J. A., Aránega A. E., Alvarez L., Aránega A. Low concentrations of actinomycin D potentially cause therapeutic differentiation in human rhabdomyosarcoma cell line RD. Pathol Res Pract. 1996 Feb;192(2):188–194. doi: 10.1016/S0344-0338(96)80219-6. [DOI] [PubMed] [Google Scholar]
  30. Melo F., Carey D. J., Brandan E. Extracellular matrix is required for skeletal muscle differentiation but not myogenin expression. J Cell Biochem. 1996 Aug;62(2):227–239. doi: 10.1002/(SICI)1097-4644(199608)62:2%3C227::AID-JCB11%3E3.0.CO;2-I. [DOI] [PubMed] [Google Scholar]
  31. Noonan K. E., Beck C., Holzmayer T. A., Chin J. E., Wunder J. S., Andrulis I. L., Gazdar A. F., Willman C. L., Griffith B., Von Hoff D. D. Quantitative analysis of MDR1 (multidrug resistance) gene expression in human tumors by polymerase chain reaction. Proc Natl Acad Sci U S A. 1990 Sep;87(18):7160–7164. doi: 10.1073/pnas.87.18.7160. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Prados J., Melguizo C., Fernandez J. E., Aranega A. E., Alvarez L., Aranega A. Actin, tropomyosin and alpha-actinin as markers of differentiation in human rhabdomyosarcoma cell lines induced with dimethyl sulfoxide. Cell Mol Biol (Noisy-le-grand) 1993 Jul;39(5):525–536. [PubMed] [Google Scholar]
  33. Prados J., Melguizo C., Fernández A., Aránega A. E., Alvarez L., Aránega A. Inverse expression of mdr 1 and c-myc genes in a rhabdomyosarcoma cell line resistant to actinomycin d. J Pathol. 1996 Sep;180(1):85–89. doi: 10.1002/(SICI)1096-9896(199609)180:1<85::AID-PATH626>3.0.CO;2-7. [DOI] [PubMed] [Google Scholar]
  34. Prados J., Melguizo C., Marchal J. A., Vélez C., Alvarez L., Aránega A. Therapeutic differentiation in a human rhabdomyosarcoma cell line selected for resistance to actinomycin D. Int J Cancer. 1998 Jan 30;75(3):379–383. doi: 10.1002/(sici)1097-0215(19980130)75:3<379::aid-ijc9>3.0.co;2-#. [DOI] [PubMed] [Google Scholar]
  35. Sartorelli A. C. The 1985 Walter Hubert lecture. Malignant cell differentiation as a potential therapeutic approach. Br J Cancer. 1985 Sep;52(3):293–302. doi: 10.1038/bjc.1985.193. [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. Skach W. R., Lingappa V. R. Transmembrane orientation and topogenesis of the third and fourth membrane-spanning regions of human P-glycoprotein (MDR1). Cancer Res. 1994 Jun 15;54(12):3202–3209. [PubMed] [Google Scholar]
  37. Vogel W., Kosmehl H., Katenkamp D., Langbein L. Differentiation dependent matrix formation (fibronectin and laminin) in an experimental murine rhabdomyosarcoma model. Acta Histochem. 1991;90(2):181–188. doi: 10.1016/S0065-1281(11)80058-9. [DOI] [PubMed] [Google Scholar]
  38. Volk T., Fessler L. I., Fessler J. H. A role for integrin in the formation of sarcomeric cytoarchitecture. Cell. 1990 Nov 2;63(3):525–536. doi: 10.1016/0092-8674(90)90449-o. [DOI] [PubMed] [Google Scholar]
  39. Waxman S., Huang Y., Scher B. M., Scher M. Enhancement of differentiation and cytotoxicity of leukemia cells by combinations of fluorinated pyrimidines and differentiation inducers: development of DNA double-strand breaks. Biomed Pharmacother. 1992;46(5-7):183–192. doi: 10.1016/0753-3322(92)90081-h. [DOI] [PubMed] [Google Scholar]
  40. Waxman S., Scher B. M., Hellinger N., Scher W. Combination cytotoxic-differentiation therapy of mouse erythroleukemia cells with 5-fluorouracil and hexamethylene bisacetamide. Cancer Res. 1990 Jul 1;50(13):3878–3887. [PubMed] [Google Scholar]
  41. Wijnaendts L. C., van der Linden J. C., van Unnik A. J., Delemarre J. F., Voute P. A., Meijer C. J. The expression pattern of contractile and intermediate filament proteins in developing skeletal muscle and rhabdomyosarcoma of childhood: diagnostic and prognostic utility. J Pathol. 1994 Dec;174(4):283–292. doi: 10.1002/path.1711740408. [DOI] [PubMed] [Google Scholar]
  42. Zupi G., Marangolo M., Arancia G., Greco C., Laudonio N., Iosi F., Formisano G., Malorni W. Modulation of the cytotoxic effect of 5-fluorouracil by N-methylformamide on a human colon carcinoma cell line. Cancer Res. 1988 Nov 1;48(21):6193–6200. [PubMed] [Google Scholar]
  43. d'Amore E. S., Tollot M., Stracca-Pansa V., Menegon A., Meli S., Carli M., Ninfo V. Therapy associated differentiation in rhabdomyosarcomas. Mod Pathol. 1994 Jan;7(1):69–75. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES